Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 + 1555 word(s) 1555 2021-06-02 11:28:05 |
2 format correct -428 word(s) 1127 2021-06-15 12:29:02 | |
3 ref corrected Meta information modification 1127 2021-06-17 08:17:18 |

Video Upload Options

Do you have a full video?

Confirm

Are you sure to Delete?
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Dudek, K. Vaccines for Bovine Mycoplasmoses. Encyclopedia. Available online: https://encyclopedia.pub/entry/10786 (accessed on 17 June 2024).
Dudek K. Vaccines for Bovine Mycoplasmoses. Encyclopedia. Available at: https://encyclopedia.pub/entry/10786. Accessed June 17, 2024.
Dudek, Katarzyna. "Vaccines for Bovine Mycoplasmoses" Encyclopedia, https://encyclopedia.pub/entry/10786 (accessed June 17, 2024).
Dudek, K. (2021, June 11). Vaccines for Bovine Mycoplasmoses. In Encyclopedia. https://encyclopedia.pub/entry/10786
Dudek, Katarzyna. "Vaccines for Bovine Mycoplasmoses." Encyclopedia. Web. 11 June, 2021.
Vaccines for Bovine Mycoplasmoses
Edit

Two of the most important diseases of cattle are caused by mycoplasmas. Mycoplasma bovis is a world-wide bovine pathogen that can cause pneumonia, mastitis and arthritis. Due to its increasing resistance to antimicrobial therapy, vaccination is the principal focus of the control of infection, but effective vaccines are currently lacking. Despite being eradicated from most parts of the world, Mycoplasma mycoides subsp. mycoides, the cause of contagious bovine pleuropneumonia (CBPP), continues to plague sub-Saharan Africa. Numerous new experimental vaccines have been developed over the last 20 years to improve on protection afforded by the T1/44, a live vaccine in continuous use in Africa for over 60 years, but none so far have succeeded; indeed, many have exacerbated the disease.

vaccine cattle Mycoplasma bovis Mycoplasma mycoides subsp. mycoides

1. Overview

Two of the most important diseases of cattle are caused by mycoplasmas. Mycoplasma bovis is a world-wide bovine pathogen that can cause pneumonia, mastitis and arthritis. It has now spread to most, if not all, cattle-rearing countries. Due to its increasing resistance to antimicrobial therapy, vaccination is the principal focus of the control of infection, but effective vaccines are currently lacking. Despite being eradicated from most parts of the world, Mycoplasma mycoides subsp. mycoides, the cause of contagious bovine pleuropneumonia (CBPP), continues to plague sub-Saharan Africa, affecting at least 25 countries. Numerous new experimental vaccines have been developed over the last 20 years to improve on protection afforded by the T1/44, a live vaccine in continuous use in Africa for over 60 years, but none so far have succeeded; indeed, many have exacerbated the disease. Tools for diagnosis and control are adequate for eradication but what is necessary are resources to improve vaccine coverage to levels last seen in the 1970s, when CBPP was restricted to a few countries in Africa. This paper summarizes the results of the main studies in the field of experimental mycoplasma vaccines, reviews data on commercially available bacterin vaccines and addresses issues relating to the search for new candidates for effective vaccines to reduce economic losses in the cattle industry caused by these two mycoplasmas.

2. Background

Mycoplasmas are the smallest self-replicating bacteria and are pleomorphic, have a low GC content and are devoid of a cell wall[1]. Out of over 200 recognized mycoplasma species, 13 have been identified in cattle, with Mycoplasma bovis and Mycoplasma mycoides subsp. mycoides being the most pathogenic and responsible for significant economic losses[2].
M. bovis is the etiological agent of many disorders in cattle with different clinical manifestations, such as pneumonia, mastitis, arthritis, otitis, keratoconjunctivitis, endocarditis and brain disorders [3]. M. bovis has the ability to form an adherent biofilm, which facilitates its survival in the host and aids the chronic course of the disease [1][4][5]. It is known that M. bovis is able to evade the host immune system most of all due to high antigenic variability of the strains, its intracellular persistence in both phagocytic and non-phagocytic cells and the immune response modulation by the bacteria[6][7][8][9]. Due to the increasing resistance of European field strains to most antimicrobials with the exception, so far, of the fluoroquinolones, and overall difficulties in M. bovis therapy, the only principal strategy for control of these infections is the use of effective vaccines[10][11]. Many studies have been done using experimental vaccines but, to date, commercially available vaccines are available only in the United States, and their efficacy is not fully satisfactory[12].
Contagious bovine pleuropneumonia (CBPP), one the great historic plagues of cattle alongside the now eradicated rinderpest, continues to inflict serious losses on livestock in many parts of sub-Saharan Africa[13]. But why is CBPP continuing to cause problems when it has been eradicated from Europe, Australia, Asia and North America? Sadly, because of economic hardships, civil wars and droughts affecting the countries where the disease is endemic and the inability to prevent transboundary movement of livestock, control in Africa seems further away than ever. CBPP is a severe pneumonia of cattle caused by the wall-less bacterium Mycoplasma mycoides subsp. mycoides. The disease is localized in the lungs, where it causes a highly characteristic “marbling” of the lungs in the acute stages and lesions known as a “sequestra” in the chronic form of the disease[14]. Clinical signs include rapid breathing, fever, nasal discharge, anorexia, cough on exertion and sudden death. Mortality rates can exceed 50% when the disease appears for the first time in herds. The mycoplasma is transmitted by close and repeated contact with aerial and environmental infection playing little or no role in its epidemiology. Consequently, it was recognized very early on that the slaughter of affected and contact animals with strict movement restrictions could effectively control the disease[15]. The difficulty, however, is identifying affected animals quickly enough to prevent the disease spreading because, though the lung may be very severely damaged, clinical signs are often lacking[16]; this was particularly true in outbreaks in European herds where cattle remain housed throughout the year. The disease is more obvious in the nomadic herds of sub-Saharan Africa where animals endure a much more hostile environment, leading to higher morbidity and mortality rates than in European cattle.

3. The Future

The successful development of protective M. bovis vaccines is still a long way off and much research is still needed in this area, especially on developing an animal challenge model. Data on the present commercial vaccines in use today are modest at best, with one showing an efficacy of 1%. Clearly, improvements need to be made before control of this fast-emerging disease is possible. What is clear, however, is that any M. bovis vaccine needs to be part of a wider vaccination program involving other respiratory pathogens, including BVD, PI3V, Mannheimia, Pasteurella and possibly others. Hopefully, the use of bioinformatics tools will allow the proteomics analysis of the M. bovis secretome and consequently the detection of novel secreted proteins that can be used not only as diagnostic biomarkers, but also in the development of a potent vaccine for effective control of M. bovis infections.
With little immediate prospect of an improved vaccine, the CBPP community does what it has done many times and produces a report providing recommendations for better vaccines[17]. While many of the proposals in the report have been recorded before, the group has also identified development of a robust challenge model as a research priority, as adult cattle are expensive, raise ethical issues and are variable in their response to M. mycoides subsp. mycoides, making experiments unreproducible. However, apart from the use of highly speculative tissue explants, there are few other surprises. It is encouraging, however, that the Global Alliance for Livestock Veterinary Medicine (GALVmed) has written: work is now proceeding to improve the performance and production processes of the existing vaccine[18]. While this will certainly help, it is annual vaccination with high coverage that remains the key to successful CBPP eradication.

References

  1. Nicholas, R.A.; Ayling, R.D. Mycoplasma bovis: Disease, diagnosis, and control. Vet. Sci. 2003, 74, 105–112.
  2. Nicholas, R.; Ayling, R.; McAuliffe, L. Mycoplasma Diseases of Ruminants, 1st ed.; CABI Publishing: Oxford, UK, 2008.
  3. Dudek, K.; Nicholas, R.A.J.; Szacawa, E.; Bednarek, D. Mycoplasma bovis Infections—Occurrence, Diagnosis and Control. Pathogens 2020, 9, 640.
  4. McAuliffe, L.; Ellis, R.J.; Miles, K.; Ayling, R.D.; Nicholas, R.A.J. Biofilm formation by mycoplasma species and its role in environmental persistence and survival. Microbiology 2006, 152, 913–922.
  5. Citti, C.; Blanchard, A. Mycoplasmas and their host: Emerging and re-emerging minimal pathogens. Trends Microbiol. 2013, 21, 196–203.
  6. Poumarat, F.; Solsona, M.; Boldini, M. Genomic, protein and antigenic variability of Mycoplasma bovis. Microbiol. 1994, 40, 305–321.
  7. Bürki, S.; Frey, J.; Pilo, P. Virulence, persistence and dissemination of Mycoplasma bovis. Microbiol. 2015, 179, 15–22.
  8. Dudek, K.; Bednarek, D.; Ayling, R.D.; Kycko, A.; Szacawa, E.; Karpińska, T.A. An experimental vaccine composed of two adjuvants gives protection against Mycoplasma bovis in calves. Vaccine 2016, 34, 3051–3058.
  9. Dudek, K.; Bednarek, D.; Lisiecka, U.; Kycko, A.; Reichert, M.; Kostro, K.; Winiarczyk, S. Analysis of the Leukocyte Response in Calves Suffered from Mycoplasma bovis Pathogens 2020, 9, 407.
  10. Dudek, K.; Bednarek, D.; Ayling, R.D.; Kycko, A.; Reichert, M. Preliminary study on the effects of enrofloxacin, flunixin meglumine and pegbovigrastim on Mycoplasma bovis BMC Vet. Res. 2019, 15, 371.
  11. Klein, U.; de Jong, A.; Youala, M.; El Garch, F.; Stevenin, C.; Moyaert, H.; Rose, M.; Catania, S.; Gyuranecz, M.; Pridmore, A.; et al. New antimicrobial susceptibility data from monitoring of Mycoplasma bovis isolated in Europe. Microbiol. 2019, 238, 108432.
  12. Soehnlen, M.K.; Aydin, A.; Lengerich, E.J.; Houser, B.A.; Fenton, G.D.; Lysczek, H.R.; Burns, C.M.; Byler, L.I.; Hattel, A.L.; Wolfgang, D.R.; et al. Blinded, controlled field trial of two commercially available Mycoplasma bovis bacterin vaccines in veal calves. Vaccine 2011, 29, 5347–5354.
  13. Egwu, G.; Nicholas, R.A.J.; Ameh, J.A.; Bashiruddin, J.B. Contagious bovine pleuropneumonia: An update. Bull. 1996, 66, 195–208.
  14. Nicholas, R.A.J.; Bashiruddin, J.B.; Ayling, R.D.; Miles, R.J. Contagious bovine pleuropneumonia: A review of recent development. Bull. 2000, 70, 827–838.
  15. Blancou, J. Early methods of surveillance and control for contagious bovine pleuropneumonia. Sci. Tech. (OIE) 1996, 1263–1282.
  16. Provost, A.; Perreau, P.; Bréard, A.; Le Goff, C.; Martel, J.L.; Cottew, G.S. Contagious bovine pleuropneumonia. Sci. Tech. (OIE) 1987, 6, 625–679.
  17. Jores, J.C.; Baldwin, C.; Blanchard, A.; Browning, G.F.; Colston, A.; Gerdts, V.; Goovaerts, D.; Heller, M.; Juleff, N.; Labroussaa, F.; et al. Contagious Bovine and Caprine Pleuropneumonia: A research community’s recommendations for the development of better vaccines. NPJ Vaccines 2020, 5, 66.
  18. A Decade of Protecting Livestock, Improving Human Lives. Available online: www.galvmed.org/galvmedat10/05-key-achievements.html (accessed on 20 March 2021).
More
Information
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
View Times: 576
Revisions: 3 times (View History)
Update Date: 23 Jun 2021
1000/1000
Video Production Service